Company Description

Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel.

The company uses its proprietary technology to develop its products comprising Capture and Contain, a containment barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients.

It develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza. The company was incorporated in 2005 is headquartered in Ra'anana, Israel.

Polyrizon Ltd.

Country	Israel
Founded	2005
IPO Date	Oct 29, 2024
Industry	Biotechnology
Sector	Healthcare
Employees	3
CEO	Tomer Izraeli

Contact Details

Address: 5 Ha-Tidhar Street Ra'anana, 4366507 Israel
Phone	972 5 5433 5665
Website	polyrizon-biotech.com

Stock Details

Ticker Symbol	PLRZ
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
IPO Price	$4.38
CIK Code	0001893645
ISIN Number	IL0011814113
SIC Code	2834

Key Executives

Name	Position
Tomer Izraeli	Founder, Chief Executive Officer and Director
Nir Ben Yosef	Chief Financial Officer
Dr. Eyal S. Ron Ph.D.	Chief Technology Officer
Daphna Avital	Chief People Officer
Dr. Tidhar Turgeman	Chief Research & Development Officer

Latest SEC Filings

Date	Type	Title
Jan 21, 2025	6-K	Report of foreign issuer
Jan 15, 2025	EFFECT	Notice of Effectiveness
Jan 10, 2025	F-1/A	[Amend] Registration statement for certain foreign private issuers
Dec 30, 2024	F-1	Registration statement for certain foreign private issuers
Dec 30, 2024	6-K	Report of foreign issuer
Dec 19, 2024	6-K	Report of foreign issuer
Dec 13, 2024	6-K	Report of foreign issuer
Dec 2, 2024	6-K	Report of foreign issuer
Oct 30, 2024	6-K	Report of foreign issuer
Oct 30, 2024	424B4	Prospectus

View All SEC Filings